The Impact of Patient Characteristics, Risk Factors, and Surgical Intervention on Survival in a Cohort of Patients Undergoing Neoadjuvant Treatment for Cervical Cancer

被引:2
作者
Dicu-Andreescu, Irinel-Gabriel [1 ,2 ]
Marincas, Marian-Augustin [1 ,2 ]
Prunoiu, Virgiliu-Mihail [1 ,2 ]
Dicu-Andreescu, Ioana [1 ]
Ionescu, Sinziana-Octavia [1 ,2 ]
Simionescu, Anca-Angela [1 ,3 ]
Bratucu, Eugen [1 ,2 ]
Simion, Laureniu [1 ,2 ]
机构
[1] Carol Davila Univ Med & Pharm, Clin Dept 10, Gen Surg, Bucharest 050474, Romania
[2] Oncol Inst Prof Dr Alexandru Trestioreanu, Dept Oncol Surg, Bucharest 022328, Romania
[3] Filantropia Clin Hosp, Dept Obstet & Gynecol, Bucharest 011132, Romania
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 12期
关键词
cervical cancer; lymph nodes; radiotherapy; radical hysterectomy; chemotherapy; stromal invasion; FIGO staging; HYSTERECTOMY; THERAPY;
D O I
10.3390/medicina59122147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Cervical cancer is among the most frequent types of neoplasia worldwide and remains the fourth leading cause of cancer death in women, a fact that raises the necessity for further development of therapeutic strategies. NCCN guidelines recommend radiation therapy with or without chemotherapy as the gold standard for locally advanced cervical cancer. Also, some studies claim that performing surgery after chemo-radiation therapy does not necessarily improve the therapeutic outcome. This study aims to determine the impact of the risk factors, various characteristics, and surgical treatment for patients in different stages of the disease on survival rate. Material and methods: Our study started as a retrospective, observational, unicentric one, carried out on a cohort of 96 patients diagnosed with cervical cancer from the surgical department of the Bucharest Oncological Institute, followed from 1 January 2019 for a period of 3 years. After the registration of the initial parameters, however, the study became prospective, as the patients were closely monitored through periodical check-ups. The end-point of the study is either the death of the participants or reaching the end of the follow-up period, and, therefore, we divided the cohort into two subgroups: the ones who survived after three years and the ones who did not. All 96 patients, with disease stages ranging from IA2 to IIIB, underwent radio-chemotherapy followed by adjuvant surgery. Results: Among the 96 patients, 45 (46%) presented residual tumor after radio-chemotherapy. Five patients (5%) presented positive resection margins at the post-operative histopathological examination. The presence of residual tumor, the FIGO stage post-radiotherapy, positive resection margins, and lympho-vascular and stromal invasions differed significantly between the subgroups, being more represented in the subgroup that reached the end-point. Variables correlated with the worst survival in Kaplan-Meier were the pelvic lymph node involvement-50% at three years (p-0.015)-and the positive resection margins-only 20% at three years (p < 0.001). The univariate Cox model identified as mortality-associated risk factors the same parameters as above, but also the intraoperative stage III FIGO (p < 0.001; HR 9.412; CI: 2.713 to 32.648) and the presence of post-radiotherapy adenopathy (p-0.031; HR: 3.915; CI: 1.136 to 13.487) identified through imagistic methods. The independent predictors of the overall survival rate identified were the positive resection margins (p-0.002; HR: 6.646; CI 2.0 to 22.084) and the post-radiotherapy stage III FIGO (p-0.003; HR: 13.886; CI: 2.456 to 78.506). Conclusions: The most important predictor factors of survival rate are the positive resection margins and the FIGO stage after radiotherapy. According to the NCCN guidelines in stages considered advanced (beyond stages IB3, IIA2), the standard treatment is neoadjuvant chemoradiotherapy. In our study, with radical surgery after neoadjuvant therapy, 46% of patients presented residual tumor at the intraoperative histopathological examination, a fact that makes the surgical intervention an important step in completing the treatment of these patients. In addition, based on the patient's features/comorbidities and the clinical response to chemotherapy/radiotherapy, surgeons could carefully tailor the extent of radical surgery, thus resulting in a personalized surgical approach for each patient. However, a potential limitation can be represented by the relatively small number of patients (96) and the unicentric nature of our study.
引用
收藏
页数:17
相关论文
共 33 条
  • [1] Oral contraceptives use and risk of cervical cancer-A systematic review & meta-analysis
    Asthana, Smita
    Busa, Vishal
    Labani, Satyanarayana
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2020, 247 : 163 - 175
  • [2] Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri
    Berek, Jonathan S.
    Matsuo, Koji
    Grubbs, Brendan H.
    Gaffney, David K.
    Lee, Susanna I.
    Kilcoyne, Aoife
    Cheon, Gi Jeong
    Yoo, Chong Woo
    Li, Lu
    Shao, Yifeng
    Chen, Tianhui
    Kim, Miseon
    Mikami, Mikio
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (02)
  • [3] Implications of the revised cervical cancer FIGO staging system
    Bhatla, Neerja
    Singhal, Seema
    Dhamija, Ekta
    Mathur, Sandeep
    Natarajan, Jayashree
    Maheshwari, Amita
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 154 (02) : 273 - 283
  • [4] Socio-economic and demographic determinants affecting participation in the Swedish cervical screening program: A population-based case-control study
    Broberg, Gudrun
    Wang, Jiangrong
    Ostberg, Anna-Lena
    Adolfsson, Annsofie
    Nemes, Szilard
    Sparen, Par
    Strander, Bjorn
    [J]. PLOS ONE, 2018, 13 (01):
  • [5] cancer, Cervical Cancer: Statistics
  • [6] Potential prognostic factors in progression-free survival for patients with cervical cancer
    Chen, Hui-Hui
    Meng, Wei-Yu
    Li, Run-Ze
    Wang, Qing-Yi
    Wang, Yu-Wei
    Pan, Hu-Dan
    Yan, Pei-Yu
    Wu, Qi-Biao
    Liu, Liang
    Yao, Xiao-Jun
    Kang, Min
    Leung, Elaine Lai-Han
    [J]. BMC CANCER, 2021, 21 (01)
  • [7] ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*
    Cibula, David
    Raspollini, Maria Rosaria
    Planchamp, Francois
    Centeno, Carlos
    Chargari, Cyrus
    Felix, Ana
    Fischerova, Daniela
    Jahnn-Kuch, Daniela
    Joly, Florence
    Kohler, Christhardt
    Lax, Sigurd
    Lorusso, Domenica
    Mahantshetty, Umesh
    Mathevet, Patrice
    Naik, Raj
    Nout, Remi A.
    Oaknin, Ana
    Peccatori, Fedro
    Persson, Jan
    Querleu, Denis
    Bernabe, Sandra Rubio
    Schmid, Maximilian P.
    Stepanyan, Artem
    Svintsitskyi, Valentyn
    Tamussino, Karl
    Zapardiel, Ignacio
    Lindegaard, Jacob
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (05) : 649 - 666
  • [8] Human papillomavirus and cervical cancer
    Crosbie, Emma J.
    Einstein, Mark H.
    Franceschi, Silvia
    Kitchener, Henry C.
    [J]. LANCET, 2013, 382 (9895) : 889 - 899
  • [9] Decker MA, 2004, AM J OBSTET GYNECOL, V191, P654, DOI 10.1016/j.ajog.2004.05.076
  • [10] Eniu Alexandru, Ghid MS Conduita Cancer Col Uterin